{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:18:33Z","timestamp":1784546313901,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00277-025-06471-2","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T08:29:33Z","timestamp":1752222573000},"page":"3753-3762","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cladribine and medium-dose cytarabine intensified busulfan plus cyclophosphamide conditioning regimen for adults high-risk B-cell acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"104","author":[{"given":"Tingting","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuanghui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"issue":"6","key":"6471_CR1","doi-asserted-by":"publisher","first-page":"e26989","DOI":"10.1002\/pbc.26989","volume":"65","author":"JL McNeer","year":"2018","unstructured":"McNeer JL, Bleyer A (2018) Acute lymphoblastic leukemia and lymphoblastic lymphoma in adolescents and young adults. Pediatr Blood Cancer 65(6):e26989","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"6471_CR2","doi-asserted-by":"publisher","first-page":"a034819","DOI":"10.1101\/cshperspect.a034819","volume":"10","author":"JAB Bispo","year":"2020","unstructured":"Bispo JAB, Pinheiro PS, Kobetz EK (2020) Epidemiology and Etiology of Leukemia and Lymphoma. Cold Spring Harb Perspect Med 10(6):a034819","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"6471_CR3","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1158\/1078-0432.CCR-21-2675","volume":"28","author":"A Bazarbachi","year":"2022","unstructured":"Bazarbachi A et al (2022) 20-year steady increase in survival of adult patients with relapsed philadelphia-positive acute lymphoblastic leukemia post allogeneic hematopoietic cell transplantation. Clin Cancer Res 28(5):1004\u20131012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6471_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3324\/haematol.2016.145631","volume":"102","author":"S Giebel","year":"2017","unstructured":"Giebel S et al (2017) Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the acute leukemia working party of the European society for blood and marrow transplantation. Haematologica 102(1):139\u2013149","journal-title":"Haematologica"},{"issue":"4","key":"6471_CR5","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.bbmt.2014.09.010","volume":"21","author":"M Mohty","year":"2015","unstructured":"Mohty M, Malard F, Savani BN (2015) High-dose total body irradiation and myeloablative conditioning before allogeneic hematopoietic cell transplantation: time to rethink? Biol Blood Marrow Transplant 21(4):620\u2013624","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"6471_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1200\/JCO.22.00767","volume":"41","author":"H Zhang","year":"2023","unstructured":"Zhang H et al (2023) Busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for adults acute B lymphoblastic leukemia: an open-label, multicenter Phase III trial. J Clin Oncol 41(2):343\u2013353","journal-title":"J Clin Oncol"},{"issue":"3","key":"6471_CR7","first-page":"e1488","volume":"5","author":"YH Wang","year":"2022","unstructured":"Wang YH et al (2022) Busulfan-containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: a Taiwan observational study. Cancer Rep (Hoboken) 5(3):e1488","journal-title":"Cancer Rep (Hoboken)"},{"issue":"12","key":"6471_CR8","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/j.bbmt.2016.09.007","volume":"22","author":"K Mitsuhashi","year":"2016","unstructured":"Mitsuhashi K et al (2016) Comparison of cyclophosphamide combined with total body irradiation, oral busulfan, or intravenous busulfan for allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 22(12):2194\u20132200","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"6471_CR9","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.3109\/10428194.2013.779691","volume":"54","author":"C Eroglu","year":"2013","unstructured":"Eroglu C et al (2013) Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant. Leuk Lymphoma 54(11):2474\u20132479","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"6471_CR10","doi-asserted-by":"publisher","first-page":"620.e1","DOI":"10.1016\/j.jtct.2021.03.026","volume":"27","author":"F Khimani","year":"2021","unstructured":"Khimani F et al (2021) Impact of total body irradiation-based myeloablative conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: systematic review and meta-analysis. Transplant Cell Ther 27(7):620.e1-620.e9","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"6471_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.clml.2023.01.004","volume":"23","author":"MEU Rehman","year":"2023","unstructured":"Rehman MEU et al (2023) Total body irradiation versus chemotherapy conditioning in pediatric acute lymphoblastic leukemia patients undergoing hematopoietic stem cell transplant: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk 23(4):249\u2013258","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"6471_CR12","doi-asserted-by":"publisher","first-page":"e28079","DOI":"10.1002\/pbc.28079","volume":"67","author":"BD Friend","year":"2020","unstructured":"Friend BD et al (2020) The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer 67(2):e28079","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"6471_CR13","doi-asserted-by":"publisher","first-page":"10079","DOI":"10.1038\/s41598-025-94556-3","volume":"15","author":"M Lv","year":"2025","unstructured":"Lv M et al (2025) Total body irradiation versus chemotherapy myeloablative conditioning in B-cell acute lymphoblastic leukaemia patients with first complete remission. Sci Rep 15(1):10079","journal-title":"Sci Rep"},{"key":"6471_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.leukres.2016.04.014","volume":"46","author":"J Fang","year":"2016","unstructured":"Fang J et al (2016) Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study. Leuk Res 46:61\u201368","journal-title":"Leuk Res"},{"issue":"2","key":"6471_CR15","doi-asserted-by":"publisher","first-page":"171.e1","DOI":"10.1016\/j.jtct.2020.10.008","volume":"27","author":"B Dholaria","year":"2021","unstructured":"Dholaria B et al (2021) Improved outcomes of haploidentical hematopoietic cell transplantation with total body irradiation-based myeloablative conditioning in acute lymphoblastic leukemia. Transplant Cell Ther 27(2):171.e1-171.e8","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"6471_CR16","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","volume":"26","author":"A D'Souza","year":"2020","unstructured":"D\u2019Souza A et al (2020) Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant 26(8):e177\u2013e182","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"6471_CR17","doi-asserted-by":"publisher","first-page":"e0228","DOI":"10.1097\/MD.0000000000010228","volume":"97","author":"J Wang","year":"2018","unstructured":"Wang J et al (2018) A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia. Medicine (Baltimore) 97(17):e0228","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"6471_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1182\/blood.V62.4.737.737","volume":"62","author":"DA Carson","year":"1983","unstructured":"Carson DA et al (1983) Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62(4):737\u2013743","journal-title":"Blood"},{"issue":"5","key":"6471_CR19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1200\/JCO.2003.05.093","volume":"21","author":"GR Goodman","year":"2003","unstructured":"Goodman GR et al (2003) Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 21(5):891\u2013896","journal-title":"J Clin Oncol"},{"issue":"16","key":"6471_CR20","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1182\/blood-2010-02-246140","volume":"116","author":"DS Sigal","year":"2010","unstructured":"Sigal DS et al (2010) Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood 116(16):2884\u20132896","journal-title":"Blood"},{"issue":"2","key":"6471_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0006-2952(02)01486-7","volume":"65","author":"D Wyczechowska","year":"2003","unstructured":"Wyczechowska D, Fabianowska-Majewska K (2003) The effects of cladribine and fludarabine on DNA methylation in K562 cells. Biochem Pharmacol 65(2):219\u2013225","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"6471_CR22","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s00277-016-2774-z","volume":"95","author":"H Park","year":"2016","unstructured":"Park H et al (2016) Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia. Ann Hematol 95(11):1777\u20131786","journal-title":"Ann Hematol"},{"issue":"3","key":"6471_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00000441-197409000-00005","volume":"268","author":"SA Armentrout","year":"1974","unstructured":"Armentrout SA, Burns CP (1974) Cytosine arabinoside as a single agent in the therapy of adult acute leukemia. Am J Med Sci 268(3):163\u2013168","journal-title":"Am J Med Sci"},{"issue":"2","key":"6471_CR24","first-page":"329","volume":"48","author":"V Gandhi","year":"1988","unstructured":"Gandhi V, Plunkett W (1988) Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 48(2):329\u2013334","journal-title":"Cancer Res"},{"issue":"6","key":"6471_CR25","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.4149\/neo_2021_210426N573","volume":"68","author":"Y Sun","year":"2021","unstructured":"Sun Y et al (2021) A novel intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of relapsed\/refractory acute myeloid leukemia. Neoplasma 68(6):1351\u20131358","journal-title":"Neoplasma"},{"key":"6471_CR26","doi-asserted-by":"publisher","first-page":"922120","DOI":"10.3389\/fonc.2022.922120","volume":"12","author":"T Cheng","year":"2022","unstructured":"Cheng T et al (2022) Comparison of outcomes of haploidentical peripheral blood stem cell transplantation supported by third-party cord blood versus human. Leukocyte antigen-matched sibling peripheral blood stem cell transplantation in hematologic malignancy patients. Front Oncol 12:922120","journal-title":"Front Oncol"},{"key":"6471_CR27","doi-asserted-by":"publisher","first-page":"980464","DOI":"10.3389\/fimmu.2022.980464","volume":"13","author":"C Zeng","year":"2022","unstructured":"Zeng C et al (2022) Haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients: a report of 80 cases. Front Immunol 13:980464","journal-title":"Front Immunol"},{"issue":"20","key":"6471_CR28","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405","journal-title":"Blood"},{"issue":"9","key":"6471_CR29","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","volume":"19","author":"PA Brown","year":"2021","unstructured":"Brown PA et al (2021) Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19(9):1079\u20131109","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"6471_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1053\/j.seminhematol.2008.09.003","volume":"46","author":"N G\u00f6kbuget","year":"2009","unstructured":"G\u00f6kbuget N, Hoelzer D (2009) Treatment of adult acute lymphoblastic leukemia. Semin Hematol 46(1):64\u201375","journal-title":"Semin Hematol"},{"issue":"1","key":"6471_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/16078454.2020.1868783","volume":"26","author":"M Lyu","year":"2021","unstructured":"Lyu M et al (2021) Comparison of autologous and allogeneic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology 26(1):65\u201374","journal-title":"Hematology"},{"issue":"11","key":"6471_CR32","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","volume":"53","author":"HM Schoemans","year":"2018","unstructured":"Schoemans HM et al (2018) EBMT-NIH-CIBMTR Task force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant 53(11):1401\u20131415","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"6471_CR33","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","volume":"21","author":"SJ Lee","year":"2015","unstructured":"Lee SJ et al (2015) Measuring therapeutic response in chronic graft-versus-host disease. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 response criteria working group report. Biol Blood Marrow Transplant 21(6):984\u201399","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"6471_CR34","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH et al (2015) National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant 21(3):389-401.e1","journal-title":"Biol Blood Marrow Transplant"},{"key":"6471_CR35","doi-asserted-by":"publisher","first-page":"605766","DOI":"10.3389\/fimmu.2021.605766","volume":"12","author":"YL Zhao","year":"2021","unstructured":"Zhao YL et al (2021) Integrating CAR T-cell therapy and transplantation: comparisons of safety and long-term efficacy of allogeneic hematopoietic stem cell transplantation after CAR T-cell or chemotherapy-based complete remission in B-cell acute lymphoblastic leukemia. Front Immunol 12:605766","journal-title":"Front Immunol"},{"issue":"2","key":"6471_CR36","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1182\/blood-2012-07-445098","volume":"121","author":"V Gupta","year":"2013","unstructured":"Gupta V, Richards S, Rowe J (2013) Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood 121(2):339\u2013350","journal-title":"Blood"},{"issue":"9","key":"6471_CR37","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00277-013-1766-5","volume":"92","author":"A Messori","year":"2013","unstructured":"Messori A et al (2013) Acute lymphoblastic leukemia in first complete remission: temporal trend of outcomes in studies comparing allogeneic transplant with autologous transplant or chemotherapy. Ann Hematol 92(9):1221\u20131228","journal-title":"Ann Hematol"},{"issue":"12","key":"6471_CR38","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1002\/cncr.31354","volume":"124","author":"T Czerw","year":"2018","unstructured":"Czerw T et al (2018) Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: an analysis by the acute leukemia working party of the EBMT. Cancer 124(12):2523\u20132533","journal-title":"Cancer"},{"issue":"17","key":"6471_CR39","doi-asserted-by":"publisher","first-page":"4936","DOI":"10.1182\/bloodadvances.2022007597","volume":"6","author":"I Aldoss","year":"2022","unstructured":"Aldoss I et al (2022) Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL. Blood Adv 6(17):4936\u20134948","journal-title":"Blood Adv"},{"issue":"1","key":"6471_CR40","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1186\/s12885-018-4670-5","volume":"18","author":"Z Shen","year":"2018","unstructured":"Shen Z et al (2018) Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis. BMC Cancer 18(1):755","journal-title":"BMC Cancer"},{"issue":"1","key":"6471_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-020-00860-y","volume":"13","author":"YJ Chang","year":"2020","unstructured":"Chang YJ et al (2020) Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study. J Hematol Oncol 13(1):27","journal-title":"J Hematol Oncol"},{"issue":"14","key":"6471_CR42","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1158\/1078-0432.CCR-15-2335","volume":"22","author":"Y Wang","year":"2016","unstructured":"Wang Y et al (2016) Haploidentical versus matched-sibling transplant in adults with Philadelphia-Negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study. Clin Cancer Res 22(14):3467\u20133476","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6471_CR43","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/bjh.14854","volume":"179","author":"LJ Han","year":"2017","unstructured":"Han LJ et al (2017) Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission. Br J Haematol 179(1):120\u2013130","journal-title":"Br J Haematol"},{"issue":"6","key":"6471_CR44","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","volume":"55","author":"A Spyridonidis","year":"2020","unstructured":"Spyridonidis A et al (2020) Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant 55(6):1114\u20131125","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"6471_CR45","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3324\/haematol.2017.185603","volume":"103","author":"R Marke","year":"2018","unstructured":"Marke R, van Leeuwen FN, Scheijen B (2018) The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia. Haematologica 103(4):565\u2013574","journal-title":"Haematologica"},{"issue":"3","key":"6471_CR46","first-page":"235","volume":"43","author":"BQ Tang","year":"2022","unstructured":"Tang BQ et al (2022) Prognostic significance of IKZF1 gene deletions in patients with B-cell acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi 43(3):235\u2013240","journal-title":"Zhonghua Xue Ye Xue Za Zhi"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06471-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06471-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06471-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T05:37:21Z","timestamp":1757223441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06471-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6471"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06471-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Xiangya Hospital, Central South University, and informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}